The prevention of atherothrombotic
events (cardiovascular death, myocardial infarction or stroke) after an Acute Coronary Syndrome in adult patients with elevated cardiac biomarkers and no prior stroke or transient ischaemic attack (TIA) when co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine
Coronary arteriography, the ultimate clinical arbiter, demonstrated atherothrombotic
occlusion in the middle portion of a dominant left circumflex coronary artery.
CSL112 may offer a novel option for rapidly stabilizing atherosclerotic lesions and is being studied for reduction in the risk of early atherothrombotic
events in acute myocardial infarction patients.
In May 2013, European Union drug regulators approved an ACS indication for rivaroxaban, to prevent atherothrombotic
events (cardiovascular death, myocardial infarction, or stroke) after an ACS in adults with elevated cardiac biomarkers, at a dose of 2.
Vascular/Immunological reaction including: acute coronary syndrome, atherothrombotic
disease, rheumatoid arthritis, psoriasis, Crohn's disease
They also suggest that, as inflammation plays a role in the development of atrial fibrillation and stroke, inflammation control is crucial for patients with rheumatoid arthritis, "not only for the management of joint symptoms, but also to reduce the need for drugs with potential adverse cardiovascular effects and, ultimately, to diminish the inflammation driven atherothrombotic
Larger studies that assess the atherothrombotic
risk due to the Lp(a) particle in hypertensive patients are needed.
This was a multi-centre, cross-sectional clinical survey of patients with atherothrombotic
events in an acute hospital setting.
Clopidogrel is a blood thinner indicated for the reduction of atherothrombotic
events for patients with a history of recent myocardial infarction, stroke or established peripheral arterial disease.
prevention of atherothrombotic
events in patients with ACS undergoing PCI.
Compared with stroke-free controls, atherothrombotic
cases had an odds ratio of 3.
Percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction can be complicated by spontaneous or angioplasty-induced embolization of atherothrombotic